BeOne在EHA 2026上展示具有里程碑意義的80歲以上CLL病患第三期資料，進一步證實BRUKINSA的獲益

Key Takeaway: The article discusses BeOne's presentation at EHA 2026, focusing on the implications of BRUKINSA for CLL patients aged 80 and above. However, the content lacks specific details about the findings or implications of the study.